Want to see IN:PANACEABIO full AI Analyst Report?
Top Page
Panacea Biotec Limited
(PANACEABIO)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹570.00
▲(59.00% Upside)
Action:Reiterated
Date:06/11/26
The score is held back primarily by weak fundamentals (ongoing losses and consistently negative free cash flow), partially offset by a strong balance sheet and solid technical momentum with the stock trading above key moving averages. Valuation is also a drag due to the negative P/E and lack of dividend yield support.
Positive Factors
Balance sheet strength
Very low leverage and sizable, stable equity gives the company financial flexibility to fund R&D, manufacturing investment or absorb tender timing. This reduces refinancing risk and supports multi‑quarter resilience while cash flows recover, a durable stability lever.
Negative Factors
Ongoing operating losses
Continued net losses into FY2026 mean the company has not yet converted revenue growth into recurring profits. Persistent losses limit retained earnings, constrain reinvestment capacity over time, and heighten dependence on balance sheet resources.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and sizable, stable equity gives the company financial flexibility to fund R&D, manufacturing investment or absorb tender timing. This reduces refinancing risk and supports multi‑quarter resilience while cash flows recover, a durable stability lever.
Read all positive factors
Panacea Biotec Limited (PANACEABIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹34.31B
Dividend YieldN/A
Average Volume (3M)12.44K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth14.43%
EPS Growth35.48%
CountryIN
Employees1,936
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.18
Shares Outstanding61,250,744
10 Day Avg. Volume14,140
30 Day Avg. Volume12,438
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)2.16
Price to Sales (P/S)2.82
P/FCF Ratio-49.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Panacea Biotec Limited Business Overview & Revenue Model
Company Description
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India,...
How the Company Makes Money
Panacea Biotec makes money primarily by selling pharmaceutical formulations and vaccines/biologics to distributors, hospitals, government/ institutional buyers, and other healthcare channels in India and selected export markets. Key revenue stream...
Panacea Biotec Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
73
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.04B | 6.40B | 5.59B | 5.52B | 4.57B | 6.59B |
| Gross Profit | 3.53B | 1.45B | 3.60B | 446.53M | 1.78B | 3.42B |
| EBITDA | 308.90M | -46.60M | 307.40M | 415.37M | 563.65M | 16.74B |
| Net Income | -72.40M | -53.70M | -83.70M | -11.73M | -332.37M | 10.78B |
Balance Sheet | ||||||
| Total Assets | 12.54B | 12.62B | 12.90B | 12.41B | 12.71B | 17.59B |
| Cash, Cash Equivalents and Short-Term Investments | 1.28B | 744.00M | 1.79B | 1.56B | 2.13B | 5.52B |
| Total Debt | 229.00M | 236.60M | 222.10M | 209.90M | 202.19M | 341.55M |
| Total Liabilities | 4.32B | 4.33B | 4.59B | 4.02B | 4.31B | 8.85B |
| Stockholders Equity | 8.26B | 8.35B | 8.35B | 8.42B | 8.44B | 8.77B |
Cash Flow | ||||||
| Free Cash Flow | -260.70M | -367.50M | -776.80M | -778.18M | -4.63B | -1.21B |
| Operating Cash Flow | -7.70M | 173.40M | -273.70M | -1.00M | -4.22B | -1.08B |
| Investing Cash Flow | -153.90M | -455.70M | 649.80M | 102.27M | 4.30B | 12.83B |
| Financing Cash Flow | -23.00M | 33.70M | -26.60M | -28.08M | -183.73M | -11.76B |
Panacea Biotec Limited Technical Analysis
Positive
358.50
Price Trends
437.65
Positive
388.91
Positive
392.98
Positive
Market Momentum
34.52
Positive
65.52
Neutral
74.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Positive. The current price of 358.5 is below the 20-day moving average (MA) of 519.68, below the 50-day MA of 437.65, and below the 200-day MA of 392.98, indicating a bullish trend. The MACD of 34.52 indicates Positive momentum. The RSI at 65.52 is Neutral, neither overbought nor oversold. The STOCH value of 74.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PANACEABIO.
Panacea Biotec Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹74.71B | 36.14 | ― | 0.13% | 18.86% | 11.25% | |
68 Neutral | ₹134.33B | 51.68 | ― | 0.80% | -12.10% | -29.87% | |
60 Neutral | ₹223.20B | -67.79 | ― | 0.08% | -3.08% | -458.85% | |
58 Neutral | ₹34.31B | -630.68 | ― | ― | 14.43% | 35.48% | |
56 Neutral | ₹673.32B | 149.10 | ― | 0.12% | 10.91% | -67.33% | |
56 Neutral | ₹176.04B | 55.51 | ― | 0.19% | 2.64% | -36.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:PANACEABIO
Panacea Biotec Limited
560.10
133.90
31.42%
IN:BIOCON
Biocon Limited
415.80
60.68
17.09%
IN:CONCORDBIO
Concord Biotech Ltd.
1,284.00
-553.15
-30.11%
IN:PPLPHARMA
Piramal Pharma Limited
167.65
-35.62
-17.52%
IN:SUPRIYA
Supriya Lifescience Limited
928.25
222.02
31.44%
IN:SYNGENE
Syngene International Ltd.
436.10
-200.95
-31.54%
Panacea Biotec Limited Corporate Events
Panacea Biotec Wins ITAT Ruling Canceling ₹9.16 Crore Tax Demand
Apr 30, 2026
Panacea Biotec said the Income Tax Appellate Tribunal in Delhi has allowed its appeal and set aside an earlier order by the Commissioner of Income Tax (Appeals) linked to a rectified assessment for FY 2019-20. The ruling deletes a ₹3.44 cror...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.